Analyst Notes: Rheumatoid Arthritis - What more should Medical Affairs be doing?

The latest FirstView Medical Affairs Reputations report puts the performance of rheumatoid arthritis medical affairs teams under the microscope and delves into their reputation amongst physicians in the US and the EU5 countries (France, Germany, Italy, Spain and the UK).

Which drugs are benefiting from the most active and supportive teams? What interactions are hitting home with physicians and prompting high satisfaction scores? What activities are valued the most and least? Ultimately, who is providing the best medical affairs services in the rheumatoid arthritis market?

Rheumatologists currently prescribing treatments for rheumatoid arthritis were surveyed to assess the reputation and performance of the medical affairs teams supporting 11 leading drugs in the US, and 12 in EU5: Actemra/RoActemra, Benepali (EU only), Cimzia, Enbrel, Humira, Inflectra, Kevzara (US only), Orencia, Remicade, Remsima (EU only), Rituxan/MabThera, Simponi and Xeljanz. The results are revealed in Medical Affairs Reputations: Rheumatoid Arthritis (2017).

Find out how each team fares against the rest, see who the star performers are and who has more to do. Choose either the US or EU5 report for a unique insight into the minds of rheumatoid arthritis drug prescribers in your preferred market.

In the US and Europe, one team strides ahead with 77 percent of physicians recalling an interaction within the last 6 months. In the US, this is down from 85 percent in 2016, with no change being seen in Europe. Does this suggest a lack of focus in the US, and could high levels of medical affairs interaction in Europe be driven by the emergence of biosimilars?

In terms of biosimilars in the US and Europe, physicians provide their views on the medical affairs performance for three brands in Europe and one in the US. Unique to this report, FirstView provides comparative benchmarking of biosimilar performance against that of the reference product, thereby allowing you to understand what's missing and what needs to be addressed in the future.

Across the US and Europe another interesting dynamic is playing out; the emergence of small-molecule therapies. These are becoming a critical component of the treatment of rheumatoid arthritis, and several more are in development (see KOL Insight: Rheumatoid Arthritis). How does the medical affairs team for the only small-molecule therapy included in the survey (Xeljanz; Pfizer) perform compared to its biologic brethren? Are they leaders, are they laggards and how does your brand compare?

Full Survey Results Now Available

All this and more, including the full survey results from either the US or EU5 can be ordered online today.

Why pay more? These revealing reports provide a robust assessment of your current medical affairs team performance without the need to commission and then await the results from expensive bespoke research.

Medical Affairs Reputations: Rheumatoid Arthritis (2017) is available now.

Purchase and download at the FirstView reports store.

Or contact FirstView for more information by calling +1 212-220-0880 or +44(0)20.7665.9240

To read more Analyst Notes articles, click here.